VERACYTE, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.5 USD | +0.08% |
|
+0.41% | -29.01% |
| Apr. 15 | Goldman Sachs Cuts Veracyte Price Target to $28 From $32, Maintains Buy Rating | MT |
| Feb. 26 | Morgan Stanley Trims Veracyte's Price Target to $21 From $22, Keeps Underweight Rating | MT |
Presenter SpeechMatthew Sykes (Analysts)Right. Thanks, everybody, for joining us. My name is M...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and assure patients. The Company offers tests for thyroid cancer (Afirma), prostate cancer (Decipher Prostate), breast cancer (Prosigna), interstitial lung diseases (Envisia), and bladder cancer (Decipher Bladder). Its Percepta Nasal Swab test is being run in its Clinical Laboratory Improvement Amendments (CLIA) lab in support of clinical studies and its tests for kidney cancer and lymphoma are in development, the latter as a companion diagnostic. Its products consist of the Prosigna breast cancer assay, the nCounter Analysis System, related diagnostic kits, and services. In the United States, it offers laboratory developed tests (LDTs), through its CLIA labs in South San Francisco and San Diego, California, supported by its cytopathology know-how in Austin, Texas. The Company also offers whole-genome MRD platform that enable it in early cancer diagnosis and risk assessment.
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
19.48
USD
Average target price
30.83
USD
Spread / Average Target
+58.28%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -29.01% | 1.46B | |
| -20.19% | 10.67B | |
| +44.25% | 3.22B | |
| -35.77% | 2.09B | |
| -17.21% | 2.04B | |
| +18.78% | 1B | |
| -4.37% | 734M | |
| -37.08% | 391M | |
| -46.12% | 379M | |
| +13.32% | 343M |
- Stock Market
- Equities
- VCYT Stock
- News Veracyte, Inc.
- Transcript : Veracyte, Inc. Presents at Goldman Sachs 43rd Annual Global Healthcare Conference, Jun-13-2022 02
